Abstract Library

#1284 Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study

Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Manon A

Authors: Manon A, Wolin E, Chassaing C, Lewis A, Bertocchi L,

Keywords: lanreotide, Somatuline, pharmacokinetic, PK,

#1175 Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials

Introduction: LAN provide antitumor effects and symptom control in NET pts.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Buil-Bruna N, Jesús Garrido M, Dehez M, Manon A, Nguyen T,

Keywords: PK, dosing,